Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMINENT phase 3 trial of felzartamab in primary membranous nephropathy
CTR20254067Phase 3Active
- Sponsor
- 不适用/ 天境生物科技（杭州）有限公司
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of felzartamab in idiopathic membranous glomerulonephritis (IMG), sponsored by 不适用/ 天境生物科技（杭州）有限公司. Started Jan 2026; status: active.
02
Drugs
felzartamab
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on CTR20254067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254067.